Table 4:
Univariate analysis of risk factors for 12 months primary patency and freedom from TLR.
| Variables | Primary Patency | p-value | Freedom from TLR | p-value | ||
| SG (n=58) | FG (n=41) | SG (n=58) | FG (n=35) | |||
| Age | 64.34±8.86 | 63.56±10.89 | 0.70 | 64.34±8.86 | 62.74±10.73 | 0.44 |
| Male (%) | 47 (81) | 37 (90.2) | 0.20 | 47 (81) | 31 (88.6) | 0.34 |
| Smoking (%) | 53 (91.4) | 32 (78) | 0.06 | 53 (91.4) | 32 (78) | 0.05 |
| DM (%) | 18 (31) | 26 (63.4) | 0.001 | 18 (31) | 22 (62.9) | 0.003 |
| HL (%) | 9 (15.5) | 17 (41.5) | 0.004 | 9 (15.5) | 14 (40) | 0.008 |
| CAD (%) | 25 (43.1) | 26 (63.4) | 0.05 | 25 (43.1) | 22 (23.7) | 0.07 |
| Occlusion | ||||||
| Length, cm | 12.51±8.36 | 16.63±78.47 | 0.018 | 12.51±8.36 | 17.79±7.76 | 0.003 |
| PACSS score (≥3) | 12 (20.7%) | 14 (34.1%) | 0.13 | 12 (20.7%) | 10 (28.6%) | 0.39 |
| Kockelkoren score (<7) | 50 (86.2%) | 29 (70.7%) | 0.06 | 50 (86.2%) | 27 (77.1%) | 0.26 |
| TASC-II (Type C+D) | 26 (44.8%) | 27 (65.9%) | 0.039 | 26 (44.8%) | 25 (71.4%) | 0.013 |
| Intraprocedural | ||||||
| Dissection | 23 (88.5%) | 19 (79.2%) | 0.46 | 16 (80%) | 23 (69.7%) | 0.41 |
| DISFORM | ||||||
| Group A | 15 (65.2%) | 12 (63.2%) | 0.89 | 9 (56.3%) | 16 (69.6%) | 0.39 |
| Group B | 8 (38.5%) | 7 (36.8%) | 7 (43.8%) | 7 (30.4%) | ||
| Variables | Primary Patency (DCB alone) | p-value | Freedom from TLR (DCB alone) | p - value | ||
| SG (n=25) | FG (n=25) | SG (n=25) | FG (n=21) | |||
| DM (%) | 6 (24) | 17 (68) | 0.002 | 6 (24) | 13 (61.9) | 0.009 |
| HL (%) | 3 (12) | 12 (48) | 0.005 | 3 (12) | 9 (42.9) | 0.018 |
| CAD (%) | 10 (40) | 18 (72) | 0.023 | 10 (40) | 15 (66.7) | 0.07 |
| Occlusion | ||||||
| Length, cm | 9.08±8.04 | 16.32±9.47 | 0.005 | 9.08±8.04 | 17.44±8.85 | 0.002 |
| PACSS score (≥3) (%) | 6 (24) | 9 (36) | 0.36 | 6 (24) | 6 (28.6) | 0.73 |
| Kockelkoren Score (<7) (%) | 21 (84) | 18 (72) | 0.30 | 21 (84) | 17 (81) | 1 |
| TASC-II (Type C+D) (%) | 6 (24) | 14 (56) | 0.021 | 6 (24) | 13 (61.9) | 0.009 |
DISFORM: Diameter reduction, spiral shape, flow impairment, or adverse morphology. TASC: Trans-Atlantic Inter-Society Consensus, PACSS: The peripheral artery calcification scoring system, Kockelkoren Score; <7 intimal dominant, ≥7 non-intimal dominant plaque formation. TLR: Target lesion revascularization, DCB: Drug coated balloon, DM: Diabetes mellitus, HL: Hyperlipidemia, CAD: Coronary artery disease, SG: Success group, FG: Failure group, Statistical significance was defined as p < 0.05. Continuous variables are presented as mean ± standard deviation.